Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mental events

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    659 result(s) found for: Mental events. Displaying page 1 of 33.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2004-000213-19 Sponsor Protocol Number: 99824 Start Date*: 2005-03-08
    Sponsor Name:Lundbeck SA
    Full Title: Sertindole versus risperidone safety outcome study: A randomised, partially-blinded, parallel-group, active-controlled, post-marketing study
    Medical condition: Schizophrenic patients most recently treated with antipsychotics other than sertindole or risperidone, requiring a new prescription for an antipsychotic, and without any contraindications for eithe...
    Disease: Version SOC Term Classification Code Term Level
    7 10037175 Psyc
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2019-003524-20 Sponsor Protocol Number: BP41316 Start Date*: 2020-12-15
    Sponsor Name:F. HOFFMANN - LA ROCHE LTD.
    Full Title: A phase II multicenter, randomized, double-blind, 12-week treatment, 3-arm, parallel-group, placebo-controlled study to investigate the efficacy, safety and tolerability of RO7017773 in participant...
    Medical condition: Autism Spectrum Disorder (ASD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000576-38 Sponsor Protocol Number: CARL Start Date*: 2022-06-08
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI CAMERINO
    Full Title: Effect of treatment of the cholinergic precursor Choline Alfoscerate in mild cognitive dysfunction
    Medical condition: Mild cognitive dysfunction
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004688-30 Sponsor Protocol Number: 15892A Start Date*: 2014-05-19
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, open-label study of 18 mg Selincro® as needed use, in the treatment of patients with alcohol dependence in primary care
    Medical condition: Alcohol Dependency
    Disease: Version SOC Term Classification Code Term Level
    16.1 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    16.1 10037175 - Psychiatric disorders 10001594 Alcohol dependence syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001017-16 Sponsor Protocol Number: FARM9A8J83 Start Date*: 2012-04-16
    Sponsor Name:IRCCS FONDAZIONE ISTITUTO NEUROLOGICO C. MONDINO
    Full Title: A randomized controlled trial of generic substitution of antiepileptic drugs
    Medical condition: Epilepsy or other diseases in which using: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, topiramate and valproate in mono or politerapy
    Disease: Version SOC Term Classification Code Term Level
    15.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    15.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003076-22 Sponsor Protocol Number: PSY-201401_ESPRIT Start Date*: 2016-07-07
    Sponsor Name:Central Institute of Mental Health Mannheim (ZI)
    Full Title: Multimodal Prevention of First Psychotic Episode – a 2x2-Factorial Randomized Trial investigating the efficacy of Acetylcysteine (ACC) and Integrated Preventive Psychological Intervention (IPPI) in...
    Medical condition: Clinical High Risk state for developing a first psychotic episode
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    20.0 10037175 - Psychiatric disorders 10061920 Psychotic disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000202-49 Sponsor Protocol Number: CN138-134 Start Date*: 2005-02-22
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Efficacy of Aripiprazole in Combination with Valproate or Lithium in the Treatment of Mania in Patients with Bipolar I Disorder Partially Nonresponsive to Valproate or Lithium Monotherapy Revised...
    Medical condition: Bipolar disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) HU (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004276-35 Sponsor Protocol Number: PI-0290-2012 Start Date*: 2014-10-10
    Sponsor Name:Hospital Regional Universitario. IBIMA
    Full Title: Phase II, Double-blind, randomized, 1-way cross-over, to investigate the effectiveness of the combination of ascorbic acid (vitamin C) and tocopherol (vitamin E) versus placebo for the treatment of...
    Medical condition: The trial aims to treat depression. The incidence of major depression in the elderly accounts for between 3.6 and 4.8% and increases to 8 to 37.4% when depressive disorders in general is studied. B...
    Disease: Version SOC Term Classification Code Term Level
    17.0 10037175 - Psychiatric disorders 10012378 Depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004647-37 Sponsor Protocol Number: G0373 Start Date*: 2006-11-06
    Sponsor Name:Bangor University
    Full Title: Folate Augmentation of Treatment – Evaluation of Depression: a randomised controlled trial
    Medical condition: Individuals with moderate to severe depression according to ICD-10 criteria.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012378 Depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-024632-42 Sponsor Protocol Number: H9P-MC-LNBN Start Date*: 2011-05-05
    Sponsor Name:Eli Lilly and Company
    Full Title: LY2216684 compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder
    Medical condition: major depressive disorder
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10012387 Depression NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) SK (Completed) GR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002093-34 Sponsor Protocol Number: NW-3509/020/III/2021 Start Date*: 2021-11-12
    Sponsor Name:NEWRON PHARMACEUTICALS SPA
    Full Title: A Phase II/III, multi-center, open-label, extension study to determine the long-term safety, tolerability, and efficacy of evenamide in patients with psychiatric disorders who participated in a pre...
    Medical condition: Patients with psychiatric disorders who participated in a previous trial with evenamide.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    21.1 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022638-96 Sponsor Protocol Number: CAFQ056B2214 Start Date*: 2011-06-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of AFQ056 in adolescent patients with Fragile X Syndrome
    Medical condition: Fragile X Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10017324 Fragile X syndrome PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) FR (Completed) DK (Completed) DE (Completed) ES (Completed) Outside EU/EEA IT (Completed) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-021044-17 Sponsor Protocol Number: CLOCK_depression Start Date*: 2010-08-11
    Sponsor Name:Medizinische Universität Wien
    Full Title: The effect of agomelatine on CLOCK gene expression in patients with major depressive disorder and healthy controls: an exploratory study.
    Medical condition: Major depressive disorder (MDD), Seasonal affective disorder (subtype of MDD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012378 Depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002157-51 Sponsor Protocol Number: 1034-PhII Start Date*: 2005-08-03
    Sponsor Name:Antares Pharma AG
    Full Title: A Phase II, Single-Center, Open-Label, Parallel, Three-Treatment, Single-Period, Randomized, Single and Multiple-Dose Pharmacokinetic Study of Oxybutynin Gel in Healthy Volunteers
    Medical condition: Study design according to CPMP/EWP/QWP/1401/98 and CPMP/EWP/280/96. Using an open-label, three-treatment, dose-ranging, single-period, randomized, single and multiple-dose design, three treatments ...
    Disease: Version SOC Term Classification Code Term Level
    6.1 10012378 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005476-41 Sponsor Protocol Number: MMHSCT1096 Start Date*: 2012-05-18
    Sponsor Name:Manchester Mental Health and Social Care Trust
    Full Title: Ketamine augmentation of ECT to improve outcomes in depression
    Medical condition: Depressive disorder requiring treatment with electroconvulsive treatment (ECT)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10012378 Depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-013667-19 Sponsor Protocol Number: CAFQ056A2212 Start Date*: 2010-11-16
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, parallel group study to evaluate AFQ056 in adult patients with Fragile X Syndrome
    Medical condition: Fragile X Syndrome
    Disease: Version SOC Term Classification Code Term Level
    15.1 10010331 - Congenital, familial and genetic disorders 10017324 Fragile X syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed) GB (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-001952-12 Sponsor Protocol Number: CAFQ056B2279 Start Date*: 2011-11-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label study to evaluate the long-term safety, tolerability and efficacy of AFQ056 in adult patients with Fragile X Syndrome
    Medical condition: Fragile X Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10017324 Fragile X syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (Prematurely Ended) DK (Prematurely Ended) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019353-18 Sponsor Protocol Number: CAFQ056B2131 Start Date*: 2011-10-31
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A sequential, open-label, two-period study to assess the pharmacokinetics, safety and tolerability of two dose levels of AFQ056 in male, adolescent patients with Fragile X Syndrome (12 to 18 years ...
    Medical condition: Fragile X Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10017324 Fragile X syndrome PT
    Population Age: Adolescents, Under 18 Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-004867-65 Sponsor Protocol Number: CAFQ056B2154 Start Date*: 2012-02-29
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Sequential, two-period study to assess the pharmacokinetics, safety & tolerability of single and multiple oral doses of AFQ056 in patients with FXS (Fragile X syndrome) aged 5-11 years (Cohort 1) a...
    Medical condition: Fragile X Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10017324 Fragile X syndrome PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-001692-39 Sponsor Protocol Number: CFTY720DDE06 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 21-week, multicenter, open label study to evaluate the safety and tolerability profile of the combination of a SSRI or SNRI antidepressive therapy with oral fingolimod in the treatment of RRMS pa...
    Medical condition: Multiple Sclerosis Depression
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10012378 Depression PT
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 09:28:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA